Jacobson Pharma Past Earnings Performance
Past criteria checks 4/6
Jacobson Pharma's earnings have been declining at an average annual rate of -0.6%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 0.2% per year. Jacobson Pharma's return on equity is 10.3%, and it has net margins of 16.2%.
Key information
-0.6%
Earnings growth rate
-0.09%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 0.2% |
| Return on equity | 10.3% |
| Net Margin | 16.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
There's Reason For Concern Over Jacobson Pharma Corporation Limited's (HKG:2633) Massive 27% Price Jump
Nov 22
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues
Dec 21Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025
Nov 27These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Nov 28Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268
Sep 25Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 28Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Jul 14Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012
Nov 29Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Sep 24Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Sep 16Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Feb 03
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)
Jan 24Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?
Dec 27Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Dec 12Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years
Dec 03Revenue & Expenses Breakdown
How Jacobson Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,563 | 253 | 335 | 0 |
| 30 Jun 24 | 1,515 | 220 | 334 | 0 |
| 31 Mar 24 | 1,468 | 186 | 332 | 0 |
| 31 Dec 23 | 1,811 | 221 | 423 | 0 |
| 30 Sep 23 | 1,401 | 141 | 328 | 0 |
| 30 Jun 23 | 1,334 | 158 | 313 | 0 |
| 31 Mar 23 | 1,268 | 175 | 298 | 0 |
| 31 Dec 22 | 1,489 | 207 | 360 | 0 |
| 30 Sep 22 | 1,427 | 203 | 347 | 0 |
| 30 Jun 22 | 1,511 | 190 | 373 | 0 |
| 31 Mar 22 | 1,596 | 178 | 398 | 0 |
| 31 Dec 21 | 1,548 | 166 | 399 | 0 |
| 30 Sep 21 | 1,501 | 154 | 400 | 0 |
| 30 Jun 21 | 1,473 | 164 | 404 | 0 |
| 31 Mar 21 | 1,446 | 174 | 408 | 0 |
| 31 Dec 20 | 1,478 | 183 | 405 | 0 |
| 30 Sep 20 | 1,510 | 191 | 403 | 0 |
| 30 Jun 20 | 1,541 | 203 | 402 | 0 |
| 31 Mar 20 | 1,571 | 214 | 401 | 0 |
| 30 Sep 19 | 1,419 | 273 | 365 | 0 |
| 30 Jun 19 | 1,449 | 259 | 353 | 0 |
| 31 Mar 19 | 1,478 | 245 | 341 | 0 |
| 31 Dec 18 | 1,663 | 235 | 343 | 0 |
| 30 Sep 18 | 1,622 | 219 | 335 | 0 |
| 30 Jun 18 | 1,585 | 211 | 337 | 0 |
| 31 Mar 18 | 1,549 | 202 | 339 | 0 |
| 31 Dec 17 | 1,486 | 202 | 321 | 0 |
| 30 Sep 17 | 1,424 | 203 | 303 | 0 |
| 30 Jun 17 | 1,340 | 191 | 304 | 0 |
| 31 Mar 17 | 1,256 | 179 | 304 | 0 |
| 31 Dec 16 | 1,188 | 142 | 316 | 0 |
| 30 Sep 16 | 1,141 | 142 | 322 | 0 |
| 30 Jun 16 | 1,112 | 144 | 307 | 0 |
| 31 Mar 16 | 1,084 | 146 | 293 | 0 |
| 31 Dec 15 | 1,043 | 145 | 275 | 0 |
| 31 Mar 15 | 948 | 102 | 246 | 0 |
| 31 Mar 14 | 926 | 172 | 266 | 0 |
Quality Earnings: 2633 has high quality earnings.
Growing Profit Margin: 2633's current net profit margins (16.2%) are higher than last year (10.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2633's earnings have declined by 0.6% per year over the past 5 years.
Accelerating Growth: 2633's earnings growth over the past year (79.7%) exceeds its 5-year average (-0.6% per year).
Earnings vs Industry: 2633 earnings growth over the past year (79.7%) exceeded the Pharmaceuticals industry 9.4%.
Return on Equity
High ROE: 2633's Return on Equity (10.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 09:46 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jacobson Pharma Corporation Limited is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cho Ming Lau | BOCI Research Ltd. |
| Wai Chak Yuen | BOCI Research Ltd. |
| Fangfang Li | Cinda International Research Limited |